Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol

Effective Treatment of Alzheimer's and Dementia With the MIND Protocol

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02260167

Acronym

MIND

Enrollment

Registered

2014-10-09

Start date

2014-09-30

Completion date

2017-12-31

Last updated

2020-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease, Dementia

Brief summary

Treating with measures that may improve metabolic functioning of neurons in an integrated protocol

Detailed description

Most organ failure results in modest drops in function until over 50% of function is lost. At a certain point, even modest drops in physiologic activity result in dramatic drops in clinical function. Though less homogeneous than in other organs, clinical experience and the literature suggests a similar process occurs in the brain. The hypothesis is that by using an integrated protocol to, essentially, tune up neuronal function, a 5-10 % improvement in metabolic functioning may translate to significant improvement in clinical functioning. This tune-up will include MIND: M- Metabolism-- optimizing hormonal function I- Infections-- looking for and eliminating N- Nutritional and herbal support D- Drugs- Weaning subjects off unneeded medications

Interventions

OTHERA mix of natural treatments and medications

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* A diagnosis of Alzheimer's and/or dementia with an MMSE score over 12 or being ambulatory and able to travel outside the home with assistance. * Must have a caregiver living with them.

Exclusion criteria

* Overt progressive and severe causes of secondary dementia such as metastatic brain cancers, or severe overt infectious encephalopathies or severe autoimmune illness. * Also, severe life threatening illnesses which would make them unlikely to be alive after 6-12 months

Design outcomes

Primary

Measure	Time frame	Description
Montreal Cognitive Assessment (MoCA)	6 months	Looking to see what percent of patients show improvement

Secondary

Measure	Time frame
Mini Mental Status Exam (MMSE)	6 months
Alzheimer's Disease Assessment Scale- Activities of Daily Living (ADAS-ADL)	6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026